Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP-Hib-IPV + MenACWY-CRM
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP-Hib-IPV + MenACWY-CRM refers to the concomitant administration of a pentavalent combination vaccine (targeting diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, and inactivated poliovirus) and a quadrivalent meningococcal conjugate vaccine. This specific immunization regimen was evaluated by Novartis Vaccines in Phase II clinical trials (such as NCT00626327) to assess the safety, immunogenicity, and B-cell memory response of the MenACWY-CRM vaccine (Menveo) when integrated into the standard infant vaccination schedule. Menveo consists of capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y, each conjugated to a non-toxic mutant of diphtheria toxin (CRM197) which serves as a carrier protein to enhance T-cell dependent immune responses. The DTaP-Hib-IPV component provides protection against five major pediatric diseases, while the MenACWY-CRM component extends protection to invasive meningococcal disease caused by the four included serogroups.
- Brand names
- Menveo
- Other names
- DTaP-Hib-IPV-Novartis Vaccines-meningococcal diseaseDTaP-Hib-IPV + MenACWY-CRMInfanrix-IPV+Hib + Menveo
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)FHA (Filamentous hemagglutinin)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on DTaP-Hib-IPV + MenACWY-CRM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP-Hib-IPV + MenACWY-CRM.